NovaBridge Biosciences (NBP)
| Market Cap | 185.60M -56.3% |
| Revenue (ttm) | n/a |
| Net Income | -117.55M |
| EPS | -1.04 |
| Shares Out | 116.00M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 197,630 |
| Open | 1.620 |
| Previous Close | 1.630 |
| Day's Range | 1.600 - 1.650 |
| 52-Week Range | 1.460 - 6.790 |
| Beta | 1.50 |
| Analysts | Strong Buy |
| Price Target | 9.00 (+462.5%) |
| Earnings Date | Aug 20, 2026 |
About NBP
NovaBridge Biosciences, a biotechnology company, engages in the research and development of immuno-oncology agents for the treatment of cancer in the United States. The company operates through two segments, Oncology and Ophthalmology. Its product pipeline comprises givastomig, a potential CLDN18.2 bispecific antibody, which is in phase 2 clinical trial combination with nivolumab and chemotherapy for the treatment of gastric cancer and other CLDN18.2-positive gastrointestinal malignancies; Phase 1b clinical trial in combination with nivolumab a... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for NBP stock is "Strong Buy." The 12-month stock price target is $9.0, which is an increase of 462.50% from the latest price.
News
NovaBridge Biosciences Transcript: H.C. Wainwright 28th Annual Global Investment Conference
The discussion highlighted a strategy of sourcing late-stage, de-risked assets globally, with lead programs givastomig and VIS-101 advancing in oncology and ophthalmology. Givastomig shows promise in low claudin expressers and is moving toward phase III, while VIS-101 aims for durable efficacy in AMD.
NovaBridge Biosciences Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference
The conference highlighted progress on a bispecific therapy for gastric cancer, with phase III trials and potential expansion into pancreatic and biliary cancers. The company is also advancing an ophthalmology asset aiming for less frequent dosing, while exploring new opportunities in women's health and global markets.
NovaBridge Appoints Martin Dewhurst to Board of Directors as an Independent Director
ROCKVILLE, Md., Sept. 08, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (Nasdaq: NBP) (“NovaBridge” or the “Company”), a global biotechnology company that identifies differentiated innovation and ap...
NovaBridge Biosciences to Participate in September Investor Conferences
ROCKVILLE, Md., Aug. 27, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (Nasdaq: NBP) (“NovaBridge” or the “Company”), a global biotechnology company that identifies differentiated innovation and app...
NovaBridge Biosciences Earnings Call Transcript: Q2 2026
Strong cash position and debt-free balance support advancement of lead programs givastomig and VIS-101, both progressing toward late-stage clinical milestones. Strategic focus includes disciplined capital allocation, European partnerships, and expansion into women's health.
NovaBridge Biosciences Earnings release: Q2 2026
NovaBridge Biosciences released its Q2 2026 earnings on August 20, 2026, summarizing the period's financial results.
NovaBridge Reports First Half 2026 Financial Results and Highlights Pipeline Momentum and Strategic Execution
ROCKVILLE, Md., Aug. 20, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (Nasdaq: NBP) (“NovaBridge” or the “Company”), a global biotechnology company that identifies differentiated innovation and app...
NovaBridge Biosciences Slides: Company presentation
NovaBridge Biosciences has posted slides in relation to its latest quarterly earnings report, which was published on August 18, 2026.
NovaBridge to Report First Half 2026 Financial Results and Provide a Corporate Update on Thursday, August 20, 2026
ROCKVILLE, Md., Aug. 13, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (Nasdaq: NBP) (“NovaBridge” or the “Company”), a global biotechnology company that identifies differentiated innovation and app...
NovaBridge Biosciences to Hold Annual General Meeting on September 8, 2026
ROCKVILLE, Md., July 24, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (Nasdaq: NBP) (“NovaBridge” or the “Company”), a clinical-stage biopharmaceutical company advancing innovative medicines for ar...
NovaBridge CEO Xi-Yong Fu to step down, Srishti Gupta to succeed
NovaBridge (NBP) announced the appointment of Srishti Gupta as CEO and a member of the company’s board of directors, effective July 1. Xi-Yong Fu will step down as CEO to…
NovaBridge Biosciences Appoints Dr. Srishti Gupta as Chief Executive Officer
ROCKVILLE, Md., June 29, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (Nasdaq: NBP) (“NovaBridge” or the “Company”), a clinical-stage biopharmaceutical company advancing innovative medicines for ar...
NovaBridge Biosciences Receives FDA Fast Track Designation for Givastomig in First-Line HER2-Negative Metastatic Gastric Cancer
Registrational Phase 3 Trial Expected to Begin as Early as Q4 2026 Detailed Phase 1b Data Expected to be Presented at a Major Medical Conference in H2 2026 ROCKVILLE, Md., June 16, 2026 (GLOBE NEWSWIR...
NovaBridge Biosciences Transcript: Jefferies Global Healthcare Conference 2026
The conference highlighted a robust pipeline in oncology and ophthalmology, with givastomig showing superior efficacy and safety in gastric cancer and VIS-101 demonstrating strong durability in wet AMD. Ample cash reserves support clinical milestones through 2028.
NovaBridge to Present at the 2026 Jefferies Global Healthcare Conference
ROCKVILLE, Md., May 28, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (Nasdaq: NBP) (NovaBridge or the Company) a global biotechnology platform company committed to accelerating access to innovative...
NovaBridge Biosciences Transcript: H.C. Wainwright 4th Annual BioConnect Investor Conference
The conference highlighted a platform-based strategy leveraging Asian biotech innovation, with lead assets givastomig (oncology) and VIS-101 (ophthalmology) advancing toward late-stage trials. Givastomig shows strong efficacy and safety in gastric cancer, while VIS-101 aims for best-in-class durability in wet AMD.
NovaBridge to Present at the H.C. Wainwright 4th Annual BioConnect Investor Conference
ROCKVILLE, Md., May 12, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (Nasdaq: NBP) (NovaBridge or the Company), a global biotechnology platform company committed to accelerating access to innovativ...
NovaBridge Appoints Mark Hagler as President and Chief Commercial Officer to Advance Commercial Strategy and Maximize Pipeline Value
Seasoned Biopharma leader bringing deep commercial experience to shape and inform corporate strategy, clinical trial design and business development discussions Strong industry reputation and commerci...
NovaBridge Biosciences Slides: Company presentation
NovaBridge Biosciences has posted slides in relation to its latest quarterly earnings report, which was published on April 15, 2026.
NovaBridge Reports Full Year 2025 Financial Results and Provides Business Update
ROCKVILLE, Md., April 07, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (Nasdaq: NBP) (“NovaBridge” or the “Company”), a global biotechnology platform company committed to accelerating access to inn...
NovaBridge Biosciences Earnings release: Q4 2025
NovaBridge Biosciences released its Q4 2025 earnings on April 7, 2026, summarizing the period's financial results.
NovaBridge Biosciences Annual report: Q4 2025
NovaBridge Biosciences has published its Q4 2025 annual report on April 7, 2026.
NovaBridge had ‘productive’ FDA meeting on potential gastric cancer treatment
The company states: “NovaBridge (NBP) Biosciences announced that based on a productive Type B meeting with the U.S. Food and Drug Administration and receipt of written minutes, NovaBridge has secured…
NovaBridge Announces Productive FDA Type B Meeting on Potential Accelerated Approval Pathway for Givastomig in Gastric Cancer
FDA confirmed givastomig's potential eligibility for an accelerated approval pathway NovaBridge expects to initiate a registrational Phase 3 combination trial as early as Q4 2026, using objective resp...
NovaBridge Biosciences Transcript: Leerink Global Healthcare Conference 2026
The company has pivoted to a platform model leveraging China-U.S. synergies, with Givastomig showing strong efficacy and safety in gastric cancer and VIS-101 demonstrating superior durability in AMD. IPO plans are delayed pending regulatory and market conditions.